Radiopharm doses first patient in RAD 402 prostate cancer trial

March 27, 2026 7:01 AM

Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in its Phase 1 clinical trial of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found